88 related articles for article (PubMed ID: 4067616)
1. Retinal toxicity after high-dose cisplatin therapy.
Wilding G; Caruso R; Lawrence TS; Ostchega Y; Ballintine EJ; Young RC; Ozols RF
J Clin Oncol; 1985 Dec; 3(12):1683-9. PubMed ID: 4067616
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanomas.
Prager TC; Kellaway J; Zou Y; Urso RG; McIntyre S; Bedikian AY
Anticancer Drugs; 1998 Jul; 9(6):515-24. PubMed ID: 9877239
[TBL] [Abstract][Full Text] [Related]
3. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Michaelides M; Stover NB; Francis PJ; Weleber RG
Arch Ophthalmol; 2011 Jan; 129(1):30-9. PubMed ID: 21220626
[TBL] [Abstract][Full Text] [Related]
4. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
Jameson MB; Sharp DM; Sissingh JI; Hogg CR; Thompson PI; McKeage MJ; Jeffery M; Waller S; Acton G; Green C; Baguley BC
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2553-9. PubMed ID: 19387077
[TBL] [Abstract][Full Text] [Related]
5. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.
Maturi RK; Yu M; Weleber RG
Arch Ophthalmol; 2004 Jul; 122(7):973-81. PubMed ID: 15249360
[TBL] [Abstract][Full Text] [Related]
6. Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Navajas EV; Krema H; Hammoudi DS; Lipton JH; Simpson ER; Boyd S; Easterbrook M
Can J Ophthalmol; 2015 Dec; 50(6):442-50. PubMed ID: 26651304
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy.
Tyni T; Kivelä T; Lappi M; Summanen P; Nikoskelainen E; Pihko H
Ophthalmology; 1998 May; 105(5):810-24. PubMed ID: 9593380
[TBL] [Abstract][Full Text] [Related]
8. Negative-type electroretinogram from cisplatin toxicity.
Marmor MF
Doc Ophthalmol; 1993; 84(3):237-46. PubMed ID: 8119103
[TBL] [Abstract][Full Text] [Related]
9. Potassium iodate toxic retinopathy: a report of five cases.
Singalavanija A; Ruangvaravate N; Dulayajinda D
Retina; 2000; 20(4):378-83. PubMed ID: 10950416
[TBL] [Abstract][Full Text] [Related]
10. Retinal toxicity associated with cisplatin and etoposide in pediatric patients.
Hilliard LM; Berkow RL; Watterson J; Ballard EA; Balzer GK; Moertel CL
Med Pediatr Oncol; 1997 Apr; 28(4):310-3. PubMed ID: 9078334
[TBL] [Abstract][Full Text] [Related]
11. Visual system toxicity following intra-arterial chemotherapy.
Kupersmith MJ; Frohman LP; Choi IS; Foo SH; Hiesinger E; Berenstein A; Wise A; Carr RE; Ransohoff J
Neurology; 1988 Feb; 38(2):284-9. PubMed ID: 3340295
[TBL] [Abstract][Full Text] [Related]
12. Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Leung LS; Neal JW; Wakelee HA; Sequist LV; Marmor MF
Am J Ophthalmol; 2015 Oct; 160(4):799-805.e1. PubMed ID: 26189086
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
[TBL] [Abstract][Full Text] [Related]
14. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Kim HS; Kang SB; Seo SS; Han SS; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
[TBL] [Abstract][Full Text] [Related]
15. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
16. Neuro-ophthalmic presentation of cone dysfunction syndromes in the adult.
Zervas JP; Smith JL
J Clin Neuroophthalmol; 1987 Dec; 7(4):202-18. PubMed ID: 2963026
[TBL] [Abstract][Full Text] [Related]
17. High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
Ozols RF; Ostchega Y; Myers CE; Young RC
J Clin Oncol; 1985 Sep; 3(9):1246-50. PubMed ID: 2993535
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.
Stewart DJ; Wallace S; Feun L; Leavens M; Young SE; Handel S; Mavligit G; Benjamin RS
Cancer Res; 1982 May; 42(5):2059-62. PubMed ID: 7199971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
